Pipeline

Greenovation has established a pipeline of proprietary drug candidates for ophan diseases like Fabry disease, C3 glomerulopathy (C3G), and Pompe disease.

Greenovation's development pipeline as of September, 2017
Greenovation's development pipeline as of September, 2017

Moss-aGal and Moss-GAA are subsitutes for human lysosomal enzymes, developed for enzyme replacement therapy (ERT), i. e. compensation for a genetically determined lack of the respective enzyme by regular infusion of biotechnologically produced substitute. In order to reach their cellular destination, the lysosomes, these biopharmaceuticals need to dock on so-called mannose-receptors which recognize and bind terminal mannose sugars of N-glycans. Being produced in moss, Greenovation's ERT products exhibit > 95 % uptake of mannose-terminated N-glycans.